Search Results
How prevalent are AKT Pathway alterations in breast cancer?
The emerging role of AKT inhibitors in breast cancer
Approval of Capivasertib for PIK3CA/AKT1/PTEN–Altered Breast Cancer: Jason Mouabbi and Carlos Doti
Metastatic HER2 Negative Breast Cancer: Emerging Novel Treatment Strategies
CAPItello-291: capivasertib +fulvestrant for AI-resistant HR+/HER2- advanced breast cancer
PI3K/Akt pathway aberrations in mCRPC
Oncogene additivity in the PI3K pathway in cancer
Dr. Arteaga on PI3K Pathway Inhibitors
Moving the Needle in ER-Positive / HER2-Negative MBC
IMPAKT 2013: The future of PI3K/AKT/mTOR inhibitors in breast cancer
Metastatic Hormone Positive Breast Cancer | 2023 KU Breast Cancer Year in Review Conference
Targeting the PI3K pathway in Breast Cancer
